FDA push­es back de­ci­sions on Ab­b­Vie's Rin­voq sNDAs to fur­ther re­view a failed Pfiz­er tri­al

Safe­ty ques­tions re­lat­ed to the lu­cra­tive class of med­i­cines known as JAK in­hibitors are con­tin­u­ing to slow the push to ex­pand their la­bels.

Ab­b­Vie on Fri­day an­nounced that the FDA said it will not meet its ac­tion dates for the sNDAs for its JAK in­hibitor Rin­voq. The com­pa­ny is seek­ing to use the drug as a treat­ment of adults with ac­tive pso­ri­at­ic arthri­tis and adults with ac­tive anky­los­ing spondyli­tis and did not say how long the de­lay will be.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.